Paper41337883
As48, a first-in-class dual-function TREM2 modulator: Receptor activation and shedding inhibition.
Cho S and 5 others. Biomed Pharmacother, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. As48, a first-in-class dual-function TREM2 modulator: Receptor activation and shedding inhibition. Papers, record 41337883. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41337883
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- As48, a first-in-class dual-function TREM2 modulator: Receptor activation and shedding inhibition.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Immunologic | Major topic |
| Membrane Glycoproteins | Major topic |
| Humans | |
| Molecular Docking Simulation | |
| Molecular Dynamics Simulation | |
| Microglia | |
| Animals | |
| Phagocytosis | |
| HEK293 Cells | |
| Phosphorylation | |
| ADAM17 Protein |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 AG083512 | NIA NIH HHS | United States | R01AG083512 | PubMed and NIH |
Source NIH RePORTER
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Update of | 40909719 |
Source PubMed
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23623698 | Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. | Neuron | 2013 | https://conductscience.org/library/papers/23623698 | PubMed |
| 2 | 33507843 | Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates. | Expert Opin Ther Pat | 2021 | https://conductscience.org/library/papers/33507843 | PubMed |
| 3 | 28930663 | The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. | Immunity | 2017 | https://conductscience.org/library/papers/28930663 | PubMed |
| 4 | 40080100 | Impact of Cancer-Associated PKM2 Mutations on Enzyme Activity and Allosteric Regulation: Structural and Functional Insights into Metabolic Reprogramming. | Biochemistry | 2025 | https://conductscience.org/library/papers/40080100 | PubMed |
| 5 | 32531244 | The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway. | Cell | 2020 | https://conductscience.org/library/papers/32531244 | PubMed |
| 6 | 12667689 | High throughput artificial membrane permeability assay for blood-brain barrier. | Eur J Med Chem | 2003 | https://conductscience.org/library/papers/12667689 | PubMed |
| 7 | 38981007 | Microglia Gravitate toward Amyloid Plaques Surrounded by Externalized Phosphatidylserine via TREM2. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/38981007 | PubMed |
| 8 | 28432014 | TREM2-Ligand Interactions in Health and Disease. | J Mol Biol | 2017 | https://conductscience.org/library/papers/28432014 | PubMed |
| 9 | 20067834 | Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. | Eur J Pharm Biopharm | 2010 | https://conductscience.org/library/papers/20067834 | PubMed |
| 10 | 28602351 | A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. | Cell | 2017 | https://conductscience.org/library/papers/28602351 | PubMed |
| 11 | 39269728 | Discovery of ICOS-Targeted Small Molecules Using Affinity Selection Mass Spectrometry Screening. | ChemMedChem | 2024 | https://conductscience.org/library/papers/39269728 | PubMed |
| 12 | 32955158 | Affinity selection-mass spectrometry for the discovery of pharmacologically active compounds from combinatorial libraries and natural products. | J Mass Spectrom | 2021 | https://conductscience.org/library/papers/32955158 | PubMed |
| 13 | 30266932 | TREM2 - a key player in microglial biology and Alzheimer disease. | Nat Rev Neurol | 2018 | https://conductscience.org/library/papers/30266932 | PubMed |
| 14 | 36635496 | A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models. | Nat Neurosci | 2023 | https://conductscience.org/library/papers/36635496 | PubMed |
| 15 | 26911435 | TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. | Nat Rev Neurosci | 2016 | https://conductscience.org/library/papers/26911435 | PubMed |
| 16 | 29518356 | TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function. | Neuron | 2018 | https://conductscience.org/library/papers/29518356 | PubMed |
| 17 | 40663973 | CHI3L1-targeted small molecules as glioblastoma therapies: Virtual screening-based discovery, biophysical validation, pharmacokinetic profiling, and evaluation in glioblastoma spheroids. | Eur J Med Chem | 2025 | https://conductscience.org/library/papers/40663973 | PubMed |
| 18 | 25728668 | TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. | Cell | 2015 | https://conductscience.org/library/papers/25728668 | PubMed |
| 19 | 33833439 | The cGAS-STING pathway as a therapeutic target in inflammatory diseases. | Nat Rev Immunol | 2021 | https://conductscience.org/library/papers/33833439 | PubMed |
| 20 | 38762085 | Coupling of surface plasmon resonance and mass spectrometry for molecular interaction studies in drug discovery. | Drug Discov Today | 2024 | https://conductscience.org/library/papers/38762085 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42812614 | TREM2-directed therapy in Alzheimer's disease: from therapeutic window to clinical translation. | Front Aging Neurosci | 2026 | https://conductscience.org/library/papers/42812614 | PubMed |
| 42445022 | High-Throughput CETSA Identifies Small Molecule Modulators of ILT3 (LILRB4) with Functional Activity in Human iPSC-Derived Microglia for Alzheimer's Disease. | ACS Med Chem Lett | 2026 | https://conductscience.org/library/papers/42445022 | PubMed |
| 41998699 | Triggering receptor expressed on myeloid cell family in atherosclerosis: from mechanisms to intervention strategies. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/41998699 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| SYK | 6850 | PubTator's text mining | https://conductscience.org/library/genes/6850 | NCBI Gene |
| TREM1 | 54210 | PubTator's text mining | https://conductscience.org/library/genes/54210 | NCBI Gene |
| TREM2 | 54209 | PubTator's text mining | https://conductscience.org/library/genes/54209 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41337883
GET https://conductscience.org/api/papers/v1/41337883/references?page=2